Cover Image
市場調查報告書

極光激酶B:開發中產品分析

Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365762
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
極光激酶B:開發中產品分析 Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 80 Pages
簡介

本報告提供以極光激酶B為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

極光激酶B 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Aeterna Zentaris Inc.
  • Amgen Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Chipscreen Biosciences Ltd
  • Merck KGaA
  • Nemucore Medical Innovations, Inc.
  • Sanofi
  • Sareum Holdings Plc
  • Vertex Pharmaceuticals Incorporated
  • Vichem Chemie Research Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0213TDB

Summary

Global Markets Direct's, 'Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1)
  • The report reviews Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Overview
  • Therapeutics Development
    • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Stage of Development
    • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Therapy Area
    • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Indication
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Companies
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Universities/Institutes
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Advenchen Laboratories, LLC
    • Aeterna Zentaris Inc.
    • Amgen Inc.
    • Astex Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Chipscreen Biosciences Ltd
    • Merck KGaA
    • Nemucore Medical Innovations, Inc.
    • Sanofi
    • Sareum Holdings Plc
    • Vertex Pharmaceuticals Incorporated
    • Vichem Chemie Research Ltd.
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Drug Profiles
    • AL-8326 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-9283 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-2811 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-2164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • danusertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ilorasertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMI-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-156497 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Aurora B Kinase for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Aurora B Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VE-465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Dormant Projects
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Discontinued Products
  • Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Featured News & Press Releases
    • May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
    • Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
    • Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors
    • Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
    • Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811
    • Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015
    • Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting
    • Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting
    • Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme
    • May 16, 2012: Astex Pharmaceuticals To Present Data On AT9283 At ASCO Annual Meeting
    • Jan 27, 2012: Cancer Research UK Launches Trial Of New Drug To Treat Acute Childhood Leukemia
    • Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Docetaxel For Treatment Of Non-Hodgkin's Lymphoma
    • Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Lenalidomide For Treatment Of Multiple Myeloma At ASH Annual Meeting
    • Nov 04, 2010: Astex And NCIC Clinical Trials Group Initiate Phase II Clinical Study Of AT9283 In Multiple Myeloma
    • Nov 23, 2009: Astex Granted Orphan Drug Status For AT9283 In AML In USA And Europe
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AbbVie Inc., H1 2016
  • Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Pipeline by Aeterna Zentaris Inc., H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Pipeline by Merck KGaA, H1 2016
  • Pipeline by Nemucore Medical Innovations, Inc., H1 2016
  • Pipeline by Sanofi, H1 2016
  • Pipeline by Sareum Holdings Plc, H1 2016
  • Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Dormant Projects (Contd..5), H1 2016
  • Dormant Projects (Contd..6), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top